Home › Calculator › EGRX Dividend Calculator 2026
EGRX Dividend Calculator 2026
No dividendHealthcareEagle Pharmaceuticals, Inc. · OTC
Price: $0.95 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
Calculator settings
EGRX is not a dividend-focused stock
EGRX pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
EGRX Dividend Yield
Eagle Pharmaceuticals, Inc. (EGRX) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When EGRX pays your bills
Year your monthly dividend income covers each expense (based on current settings)
About Eagle Pharmaceuticals, Inc. (EGRX) — Dividend Analysis 2026
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
EGRX Dividend & DRIP — Frequently Asked Questions
Does EGRX pay a dividend?
No. Eagle Pharmaceuticals, Inc. (EGRX) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
How can I get dividend income instead of EGRX?
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
Does EGRX have a DRIP (dividend reinvestment plan)?
A DRIP reinvests dividends into new shares. EGRX has no regular dividend in our data, so there is nothing to reinvest.
Stocks similar to EGRX
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full EGRX DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open EGRX position with:
🌍 EGRX Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold EGRX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 EGRX Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 EGRX Dividend Payment Schedule
EGRX pays quarterly — 4 times per year. Ex-div: —.
📊 EGRX vs Healthcare Benchmarks
How EGRX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for EGRX sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ EGRX Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| F-InKind | 2024-02-28 | 2,119 | $6.27 | $13.3K | ||
| A-Award | 2024-02-27 | 3,800 | — | — | ||
| F-InKind | 2024-02-27 | 1,589 | $6.44 | $10.2K | ||
| A-Award | 2024-02-27 | 12,950 | — | — | ||
| F-InKind | 2024-02-27 | 3,154 | $6.44 | $20.3K | ||
| F-InKind | 2024-02-02 | 934 | $5.85 | $5.5K | ||
| F-InKind | 2024-01-05 | 735 | $5.13 | $3.8K | ||
| F-InKind | 2024-01-05 | 4,322 | $5.13 | $22.2K | ||
| A-Award | 2023-12-21 | 293,000 | $5.01 | $1.47M | ||
| F-InKind | 2023-12-18 | 452 | $4.76 | $2.2K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Peer Group
Similar companies in the same sectorCompare EGRX with peers: EGRX vs BLMH · EGRX vs CLCFF · EGRX vs CNFHF
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the EGRX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Eagle Pharmaceuticals, Inc. (EGRX) is currently trading at $0.95, 75% below its 52-week high. It does not currently pay a regular dividend.
Does EGRX Pay a Dividend? Eagle Pharmaceuticals, Inc. Dividend Status
Eagle Pharmaceuticals, Inc. (EGRX) is a healthcare stock trading at $0.95. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
- Without a dividend, returns depend entirely on the share price.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest EGRX News
LiveProjected your EGRX DRIP returns?
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.